Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 dec 2008 - 13:57
Statutaire naam
Crucell N.V.
Titel
Crucell Signs Second Exclusive License Agreement with Talecris Biotherapeutics
Bericht
Leiden, The Netherlands (December 17, 2008) – Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it has signed a second exclusive, commercial license agreement with North Carolina-based Talecris Biotherapeutics for an undisclosed and specific protein and the exclusive rights to produce that protein using the PER.C6® cell line.
Crucell will receive an upfront payment of $1.5 million following the execution of the agreement and will be eligible for milestone payments of approximately $20 million. Further financial details of the agreement were not disclosed.
In September Crucell announced that it had signed an exclusive, commercial license agreement with North Carolina-based Talecris Biotherapeutics also for an undisclosed and specific protein and the exclusive rights to produce that protein using the PER.C6® cell line. For that deal Crucell received an upfront payment of $2.5 million and is eligible for milestone payments of approximately $30 million across multiple indications.
Datum laatste update: 03 januari 2026